Published in
Nature Research, Nature Communications, 1(14), 2023
DOI: 10.1038/s41467-023-35969-4
Links
Tools
Author Correction: Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer
Journal article published in 2023 by
R. C. Coombes 
,
P. D. Badman ,
J. P. Lozano-Kuehne ,
X. Liu,
I. R. Macpherson ,
I. Zubairi,
R. D. Baird ,
N. Rosenfeld ,
J. Garcia-Corbacho ,
N. Cresti ,
R. Plummer,
A. Armstrong,
R. Allerton,
D. Landers ,
H. Nicholas
and other authors.
,
P. D. Badman ,
J. P. Lozano-Kuehne ,
X. Liu,
I. R. Macpherson ,
I. Zubairi,
R. D. Baird ,
N. Rosenfeld ,
J. Garcia-Corbacho ,
N. Cresti ,
R. Plummer,
A. Armstrong,
R. Allerton,
D. Landers ,
H. Nicholas
and other authors.
This paper is made freely available by the publisher.
Full text: Download
Postprint:
archiving forbidden
Data provided by 